Company news

Immatics N.V. news in 2021

Immatics N.V.'s news releases, calls and decks from 2021, newest first.

View company

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

December 13, 2021

Immatics Announces Third Quarter 2021 Financial Results and Provides Business Update

November 15, 2021

Immatics Reports Clinical Responses across Multiple Solid Tumor Types in Ongoing ACTengine® IMA203 Phase 1a Trial Targeting PRAME

November 8, 2021

Immatics Announces Second Quarter 2021 Financial Results and Provides Business Update

August 9, 2021

Immatics Announces Changes to its Board of Directors

May 25, 2021

Immatics Announces First Quarter 2021 Financial Results and Business Update

May 17, 2021

Immatics Presents Preclinical Proof-of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

May 10, 2021

Immatics Announces Full Year 2020 Financial Results and Corporate Update

March 29, 2021

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

March 16, 2021

Decks in 2021